Table 2.
Univariate analysis of the predictors in 24 patients with pancreatic cancer after operation
| Parameter | Number | Metastasis | DFS | OS | |||
|---|---|---|---|---|---|---|---|
| Hazard ratio(95% CI) | P-value | Hazard ratio(95% CI) | P-value | Hazard ratio(95% CI) | P-value | ||
| Age(years) | 0.565 | 0.706 | 0.202 | ||||
| <65 | 14 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| ≥65 | 10 | 0.992(0.277–3.546) | 1.259(0.381–4.159) | 3.324(0.525–21.037) | |||
| Gender | 0.99 | 0.356 | 0.189 | ||||
| Male | 12 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| Female | 12 | 1.451(0.408–5.167) | 1.79(0.52–6.159) | 4.358(0.486–39.102) | |||
| Portal EpCAM + CD45 − count (/5 mL) | 0.357 | 0.27 | 0.526 | ||||
| <60 | 7 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| ≥60 | 17 | 2.68(0.329–21.798) | 3.22(0.402–25.766) | 33.42(0.001–1,722,476.278) | |||
| Portal EpCAM + CD45 − percentage (×10−4) | 0.025 | 0.03 | 0.891 | ||||
| <24.5 | 12 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| ≥24.5 | 12 | 10.757(1.354–85.446) | 5.525(1.183–25.802) | 1.136(0.182–7.087) | |||
| Peripheral EpCAM + CD45 − count (/5 mL) | 0.17 | 0.11 | 0.438 | ||||
| <97 | 9 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| ≥97 | 14 | 4.404(0.53–36.598) | 5.53(0.679–45.045) | 44.932(0.003–677,395.075) | |||
| Missing | 1 | ||||||
| Peripheral EpCAM + CD45 − percentage (×10−4) | 0.201 | 0.139 | 0.431 | ||||
| <4.4 | 8 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| ≥4.4 | 15 | 3.925(0.483–31.865) | 4.806(0.6–38.477) | 36.017(0.005–266,995.789) | |||
| Missing | 1 | ||||||
| CEA (ng/mL) | 0.668 | 0.668 | 0.444 | ||||
| <5 | 15 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| ≥5 | 7 | 0.742(0.189–2.908) | 0.742(0.189–2.908) | 2.151(0.302–15.304) | |||
| Missing | 2 | ||||||
| CA125 (U/mL) | 0.522 | 0.504 | 0.662 | ||||
| <35 | 20 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| ≥35 | 1 | 0.04(0–741.996) | 0.041(0–484.606) | 0.043(0–59,614.482) | |||
| Missing | 3 | ||||||
| CA19-9(U/mL) | 0.119 | 0.19 | 0.841 | ||||
| <39 | 5 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| ≥39 | 18 | 0.318(0.075–1.342) | 0.394(0.098–1.585) | 0.797(0.087–7.295) | |||
| Missing | 1 | ||||||
| CA242(U/mL) | 0.077 | 0.043 | 0.311 | ||||
| <3.5 | 10 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| ≥3.5 | 11 | 4.193(0.857–20.525) | 5.041(1.055–24.097) | 63.835(0.021–198,399.215) | |||
| Missing | 3 | ||||||
| Differentiation | 0.931 | 0.919 | 0.685 | ||||
| Well to moderate | 5 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| Others | 19 | 0.934(0.196–4.448) | 1.083(0.232–5.059) | 0.632(0.069–5.799) | |||
| Size | 0.247 | 0.185 | 0.752 | ||||
| ≤2 cm | 7 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| >2 cm | 17 | 2.537(0.524–12.278) | 2.862(0.604–13.565) | 0.748(0.123–4.539) | |||
| Lymphatic metastasis | 0.385 | 0.595 | 0.594 | ||||
| Negative | 12 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| Positive | 12 | 0.571(0.161–2.025) | 0.725(0.221–2.377) | 0.614(0.102–3.686) | |||
| Neural invasion | 0.725 | 0.699 | 0.844 | ||||
| Negative | 1 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| Positive | 23 | 21.549(0–571,331,677.8) | 21.609(0–126,561,461.2) | 21.452(0–3.79267E+14) | |||
| Lymphovascular tumor embolus | 0.364 | 0.248 | 0.948 | ||||
| Negative | 14 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| Positive | 10 | 0.534(0.138–2.068) | 0.457(0.121–1.726) | 0.942(0.157–5.639) | |||
| AJCC-stage | 0.385 | 0.595 | 0.594 | ||||
| < II B | 12 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| ≥ II B | 12 | 0.571(0.161–2.025) | 0.725(0.221–2.377) | 0.614(0.102–3.686) | |||
| R | 0.543 | 0.76 | 0.328 | ||||
| R0 | 13 | 1(Referent) | 1(Referent) | 1(Referent) | |||
| R1 | 11 | 1.474(0.422–5.147) | 1.205(0.364–3.99) | 2.465(0.404–15.039) | |||